搜索
Search
img
苏州开拓药业股份有限公司
专注于大量未被满足临床需求的疾病领域
PREV
NEXT
苏州开拓药业股份有限公司
苏州开拓药业股份有限公司

About Us

We concentrate on cancers and other high-incidence diseases to fulfill numerous unmet medical needs. Our particular expertise is in Androgen Receptor related diseases

Including prostate cancer, breast cancer, liver cancer, alopecia and other diseases that not only affect a large number of patients but also lack effective treatments

Our diverse product pipeline is built on a foundation of internal R&D and supplemented with external licensing. We are committed to provide the best therapeutics for our patients

这是描述信息
这是描述信息

Small-molecule innovative drugs

The product pipeline primarily focuses on AR antagonists and was subsequently expanded to include mTOR inhibitors, Hedgehog inhibitors, AR protein degradation agents and cMyc inhibitors.

这是描述信息

Innovative biologics

Our first novel biologic drug, an ALK-1 antibody licensed from Pfizer, is expected to become a "first-in-class" biologic for multiple cancers. From this project , Kintor biologics start to layout in the biologics area.

这是描述信息

Combination therapy

In order to provide the best treatment plan for prostate cancer, breast cancer, liver cancer and other deseases, we are creating diverse combination therapies with our own innovative drugs at core.

Our Platform

R&D Platform

We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.

Manufacturing Base

A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.

Commercial Operation

 In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.

R&D Platform

 We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.

Manufacturing Base

A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.

Commercial Operation

 In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.

News Center

2020-06-28

Kintor Pharmaceutical Signs Strategic Cooperation Agreement with JD Pharmacy

(28 June 2020 – Hong Kong) Kintor Pharmaceutical Limited announced that it has signed a strategic cooperation framework agreement with JD Pharmacy, the pharmaceutical retail channel under JD Health, in a concerted effort to create a patient-centred online innovative healthcare ecosystem. JD Pharmacy will utilise its abundant traffic and resources and strong technological and supply chain capabilities to assist Kintor Pharmaceutical in the marketing and sales of the innovative External use drug KX-826.

2020-05-22

Kintor Pharmaceutical successfully listed on HKEX today

Kintor Pharmaceutical Limited (Stock Code:9939.HK) has successfully been listed on the Main Board of the Stock Exchange of Hong Kong Limited on 22,May 2020.

2020-05-19

XIEYI Characters丨Youzhi Tong: To be listing on HKEX, victory at a steady pace over a long 11 years’ journey!

On the last day of 2019, Kintor’s application for a HKEX listing had attracted industry attention. It was reported that with this Hong Kong stock IPO listing on May 22nd 2020 and the global sale of 92

Talent Recuritment

这是描述信息
这是描述信息

News Center

Company News    Media Reports

Contact Us

Find Us

这是描述信息